75 results
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
15 May 24
VBI Vaccines Reports First Quarter 2024 Financial Results
4:18pm
product sales.
Research and Development (R&D): R&D expenses for the first quarter of 2024 were $2.6 million as compared to $3.2 million for the same … period in 2023. R&D expenses were offset by $0.7 million for the three months ended March 31, 2024, and $2.4 million for the three months ended March 31
8-K
EX-99.1
VBIVQ
VBI Vaccines Inc
16 Apr 24
VBI Vaccines Reports Full Year 2023 Financial Results
8:00am
revenue and R&D services revenue associated with the agreements with Brii Bio.
Cost of Revenues: Cost of revenues was $12.5 million for the full year … during the year ended December 31, 2023.
Research and Development (R&D): R&D expenses for the year ended December 2023 were $9.3 million as compared
8-K
EX-99.1
o16ti 9cjz
14 Nov 23
VBI Vaccines Reports Third Quarter 2023 Financial Results
4:07pm
8-K
EX-99.1
ei1uqsx 288
14 Aug 23
VBI Vaccines Reports Second Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
avin3d8qv2e8x w51
15 May 23
VBI Vaccines Reports First Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
zdojxt40e0fdzgkhgr9d
6 Dec 22
Entry into a Material Definitive Agreement
9:25am
8-K
EX-99.1
2x9 x6yqybk2
10 Nov 22
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
b7vgy
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
tbvmwkgw
9 May 22
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am